- Home
- OPTX vs NRXP Comparison
OPTX vs NRXP Comparison
Compare OPTX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPTX | NRXP |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 63.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPTX | NRXP |
|---|---|---|
| Price | $1.53 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 136.7K | ★ 461.9K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,900,395.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $1.17 |
| 52 Week High | $5.10 | $6.01 |
Technical Indicators
Market Signals| Indicator | OPTX | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 37.62 |
| Support Level | $1.39 | $2.22 |
| Resistance Level | $1.62 | $2.39 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 49.30 | 4.26 |
Price Performance
Historical ComparisonAbout OPTX Syntec Optics Holdings Inc.
Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.